Scientific American is recognized as the oldest continuously published magazine in the nation. The magazine has been bringing its readers unique insights about developments in science and technology for more than 150 years. Recently, Scientific American focused its attention on Performance Health Technologies, Inc. (PFMH.OB) and its revolutionary technologies.

Although Performance Health Technologies’ products reach into multiple markets, the magazine focused on the rehabilitation of sports injuries. Sports have become a crucial part of many Americans’ lives, making questions such as “how will the Ravens do now that their starting quarterback is out of season with a shoulder injury” quite important. According to SGMA, the U.S. sporting goods industry alone is worth $68.4 billion.

Performance Health Technologies designed their Core:TX wireless motion-sensing rehabilitation system to improve the rehabilitation process. A physical therapy patient or stroke victim simply wears a small, wireless sensor near

Performance Health Technologies, Inc. is a New Jersey based company that develops and markets performance evaluation and rehabilitation products that monitor and guide exercise and give real-time motivational feedback. With an array of talented members on the Performance team, the young company’s products have been tested, accepted, and endorsed by leaders in the medical, rehabilitation and athletic communities.

While Performance Health has branched out into many markets, the company has begun to make its mark in three distinct fields: Rehabilitation, Fitness and Home Care. Within each of these markets, Performance has taken a lead role in the business world and has positioned itself to become a force in the marketplace.

In the rehabilitation field, Performance has gained national recognition for their breakout product SportsRAC. SportsRac is designed to help rehabilitate professional baseball players from rotator cuff surgery. SportsRac is

Oxygen Biotherapeutics, Inc. is a pharmaceutical company dedicated to oxygen therapies and continuous substrate monitoring. For those unfamiliar with oxygen therapies, it refers to products that mimic human blood’s oxygen transport ability. Oxygen therapeutics are in turn broken into two categories based on transport mechanism: perfluorocarbon based, and hemoglobin based.

The Company has under development a perfluorocarbon therapeutic oxygen carrier and liquid ventilation product (Oxycyte®) and an implantable glucose sensor. Oxycyte®, once commercialized, may help patients recover from traumatic brain injury, sickle cell crisis pain, trauma, wound care, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, and diabetes.

Yesterday the company announced that the animal studies conducted using rats given different doses of Oxycyte showed improved brain cognitive ability after brain trauma. The researchers found that injured animals treated with a dose of Oxycyte had significant improvement in ability to learn. The ability to learn and perform complex tasks (a maze)

Performance Health Technologies, Inc. is offering a new and sophisticated way for people to interact with their own bodies. Bringing together medical and computer experts, the company has combined advanced software and medical technologies to create MotionTrack™, a proprietary technology platform that can track and monitor detailed body movements and motion in real time, providing immediate visual feedback to the user. The company’s goal is not only to transform the way individuals exercise and train for sports, but also to revolutionize rehabilitation from injuries, providing more efficient and controlled therapy.

Performance Health’s innovative products are gaining wide acceptance, and endorsement, by medical, rehabilitation, and athletic communities, and were recently featured in Scientific American Online. The products are now being used by orthopedic surgeons, neurologists, occupational and physical therapists, and even speech pathologists.

The popularity is due in part to the success experienced by patients recovering

There are innumerable instances in which unfortunate medical circumstances create a need for neurological and muscular rehabilitation therapies. Answering the call is Performance Health Technologies, a leader in advanced physical therapy aids targeted at accelerating the recovery of stroke victims, injured athletes, and sufferers of a wide range of neuromuscular disorders.

Developed by the company’s staff of medical professionals and IT experts, the MotionTrack biofeedback monitoring platform is the foundation upon which PHT’s impressive line of products are built. Using a set of proprietary software algorithms in conjunction with state-of-the-art inertial sensors, the MotionTrack system is designed to wirelessly detect and monitor patient movement.

This platform provides the basis for PHT’s Core:Tx neuromuscular training aid, which consists of two versions: Core:Tx Professional for clinical use, and Core:Tx Home Therapies, for the continuation of a patient’s therapy upon departure from the hospital. Core:Tx Pro

Oxygen Biotherapeutics Inc. (OTCBB: OXBO) engages in marketing innovative pharmaceuticals and medical devices to monitor respiration in patients suffering from or associated with respiratory distress syndrome, stroke, myocardial infarction, surgery, trauma, malignant tumors and diabetes.

The company today announced it will submit an amended test protocol to the U.S. Food and Drug Administration, as well as in Canada, to cover the dose escalation studies of the company’s therapeutic oxygen carrier Oxycyte. The company plans on recruiting 40 traumatic brain injury (TBI) patients in each country to test the safety and efficacy of Oxycyte.

“Personally, I think that the extensive data we will collect in the dose escalation studies should be more than needed for proof-of-concept in both safety and efficacy. The advantage is that we should have the data we need much earlier, after each cohort of 10, rather than after 200 patients as it was previously planned. Another important

Implementing its highly-advanced Core:Tx® neuromuscular training system, Performance Health Technologies evaluates and treats stroke victims, as well as individuals struggling with a wide range of neurological disorders.

Core:Tx® is the ultimate in rehabilitation technology, working both as a physical therapy aid and a next-generation biofeedback analysis tool. Comprised of a hardware and software system, the Core:Tx® platform is wirelessly connected to the patient, and monitors in real-time, the position and movement of selected areas of the body.

Patients already benefitting from this ingenious recovery-aid platform include those with nervous system damage from stroke, MS, tumors, and brain injury due to trauma. It helps sufferers cope with the loss of motor control that often accompanies cases that involve severe nerve damage, in addition to aiding in post-surgical recovery.

Physical therapists now have a new tool to assist them in returning the lives

Our Director of Marketing’s Grandfather died of a massive brain tumor when she was only about a year old. His last days were a combination of comatose and automatic speaking. He recited every line that he had ever spoken on stage (he was in the entertainment industry). Although she doesn’t remember it, it was very traumatic for her family.

Recurrent Glioblastoma Multiforme is the most common type of malignant primary brain tumor in adults. Treatment success has not significantly changed over the last 20 years, with most patients living less than one year after diagnosis despite aggressive surgery, radiation and chemotherapy. Additionally, Brain stem cell cancer is the most lethal cancer in children, with a survival rate of less than one year after diagnosis.

NeoPharm’s agreement with NINDS will serve as another step in pursuing the validation of the company’s proprietary drug, Cintredekin Besudotox (IL13-PE38QQR) (“IL-13”) and its impact on possibly

Neurobiological Technologies, Inc. (NASDAQ: NTII) announced that a recent meeting with the U.S. Food and Drug Administration to discuss a Phase 3 Clinical trial for its Viprinex was encouraging.

As a result, the company will consolidate data and patients from its two other trials into a single Phase 3 pivotal trial to be completed by mid-2009. Viprinex is designed to assist with the treatment of acute ischemic stroke. Interim trial results are now expected in January 2009.

“Since the two concurrent Phase 3 studies employ the same protocol and patient entry criteria, the validity of the single merged study remains the same as initially designed for the two individual studies,” a company news release states.

“This is game-changing for us, our shareholders and patients,” said Paul E. Freiman, president and CEO. “… If results are positive, we will be able to move the program forward with much more information and a higher level

Neurobiological Technologies, Inc. (NASDAQ: NTII) announced that a recent meeting with the U.S. Food and Drug Administration to discuss a Phase 3 Clinical trial for its Viprinex was encouraging.

As a result, the company will consolidate data and patients from its two other trials into a single Phase 3 pivotal trial to be completed by mid-2009. Viprinex is designed to assist with the treatment of acute ischemic stroke. Interim trial results are now expected in January 2009.

“Since the two concurrent Phase 3 studies employ the same protocol and patient entry criteria, the validity of the single merged study remains the same as initially designed for the two individual studies,” a company news release states.

“This is game-changing for us, our shareholders and patients,” said Paul E. Freiman, president and CEO. “… If results are positive, we will be able to move the program forward with much more information and a higher level